MedTrace Logo

Novel Vascular Biomarkers Behaviour and Clinical Value in Heart Failure and CRT

NCT02541773 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2016-03-09

No results posted yet for this study

Summary

The purpose of this study is to understand the behaviour of certain blood markers in patients with heart failure who undergo a cardiac device implantation procedure called cardiac resynchronization therapy (CRT). CRT is an effective treatment for heart failure, but up to 30% of people do not respond and have poor outcomes (1,2). Despite extensive investigation, identifying these patients continues to be a challenge. The study intends to describe the changes in these blood markers before and after CRT and to examine any potential clinical value.

The idea behind the study is that these blood markers alter in heart failure and change with CRT implantation. Furthermore the pattern of marker expression before implant and after may predict response and outcome.

Conditions

Interventions

DEVICE

Cardiac Resynchronisation Therapy

Routine implantation of CRT - part of standard of care

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • University Hospitals Coventry and Warwickshire NHS Trust

    lead OTHER

Principal Investigators

  • Faizel Osman, MD FRCP FESC · University Hospital Coventry and Warwickshire

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02541773 on ClinicalTrials.gov